chikungunya
viru
chikv
mosquitotransmit
alphaviru
caus
chikungunya
fever
infect
million
peopl
mainli
develop
countri
associ
diseas
character
rash
high
fever
sever
arthriti
persist
year
sinc
epidem
la
chikv
adapt
aed
albopictu
also
inhabit
temper
region
eastern
western
hemispher
includ
europ
unit
state
albopictu
might
continu
migrat
north
continu
climat
chang
chikv
would
longer
confin
develop
nation
treatment
licens
chikv
vaccin
exist
chikv
neutral
assay
format
use
chikvpseudotyp
lentivir
vector
establish
assay
system
use
entri
inhibitor
screen
reduc
safeti
level
product
chikvpseudotyp
lentivir
vector
reaction
volum
optim
dose
depend
specif
neutral
chikvpseudotyp
vector
sera
chikvinfect
individu
could
measur
format
safe
simpl
multiplex
assay
analysi
chikv
neutral
activ
develop
abl
improv
drug
vaccin
develop
well
would
improv
understand
chikv
epidem
regard
antibodi
respons
chikungunya
viru
chikv
mosquitotransmit
alphaviru
caus
chikungunya
fever
human
chikv
infect
symptomat
incub
period
day
diseas
character
sudden
onset
fever
headach
malais
arthralgia
arthriti
myalgia
lower
back
pain
term
chikungunya
mean
bend
kimakond
languag
mozambiqu
describ
diseas
phenotyp
acut
phase
polyarthr
recurr
may
persist
sever
year
infect
factor
rais
seriou
public
health
concern
contribut
signific
econom
cost
larg
outbreak
chikv
first
isol
blood
febril
patient
tanzania
sinc
identifi
caus
numer
human
epidem
mani
area
africa
southeast
asia
indian
subcontin
thiboutot
et
al
schwartz
albert
aed
aegypti
primari
chikv
vector
asia
la
aed
albopictu
asian
tiger
mosquito
primari
vector
solignat
et
al
epidem
chikv
adapt
effect
albopictu
also
inhabit
temper
even
cold
temper
region
eastern
western
hemispher
includ
europ
unit
state
medlock
et
al
rochlin
et
al
albopictu
might
continu
migrat
north
continu
climat
chang
chikv
would
longer
confin
develop
nation
risk
introduc
chikv
previous
nonendem
area
exist
travel
viremia
lead
local
transmiss
viru
especi
tropic
subtrop
area
unit
state
also
southern
europ
rezza
et
al
result
niaid
design
chikv
categori
c
pathogen
alongsid
influenza
sarscov
virus
specif
treatment
chikungunya
fever
care
support
base
symptom
licens
chikv
vaccin
exist
chikv
singl
strand
ss
rna
viru
belong
alphaviru
genu
togavirida
famili
alphavirus
enter
cell
receptor
mediat
endocytosi
subsequ
phdepend
fusion
step
chikv
three
surfac
protein
two
transmembran
glycoprotein
mainli
secret
protein
presum
facilit
secret
glycoprotein
mayn
et
al
snyder
mukhopadhyay
class
ii
viral
fusion
protein
like
mediat
cell
attach
howev
cellular
receptor
still
unknown
associ
trimer
heterodim
particl
surfac
voss
et
al
earli
step
infect
receptor
bind
membran
fusion
carri
sole
viral
glycoprotein
addit
glycoprotein
major
target
neutral
antibodi
respons
tool
use
investig
glycoprotein
virus
pseudotyp
vector
desir
glycoprotein
strategi
vector
incorpor
heterolog
viral
glycoprotein
therebi
acquir
host
rang
viru
glycoprotein
deriv
enabl
studi
without
need
use
nativ
viru
usual
requir
higher
safeti
level
pseudotyp
retroor
lentivir
vector
frequent
use
studi
viral
entri
evalu
entri
inhibitor
siegert
et
al
harvest
neutral
antibodi
reduc
safeti
level
schnierl
et
al
seaman
et
al
dervillez
et
al
previous
describ
lentivir
vector
pseudotyp
chikv
transfer
chikv
host
rang
vector
salvador
et
al
akahata
et
al
kishishita
et
al
vector
system
use
creat
reduc
safeti
level
assay
analyz
sera
chikvinfect
individu
neutral
activ
therebi
establish
multiplex
assay
format
analysi
compound
abl
inhibit
chikv
entri
cell
use
studi
cultur
c
co
hela
atcc
hek
nih
ht
cell
grown
dulbecco
modifi
eagl
medium
dmem
lonza
vervier
belgium
renca
hacat
boukamp
et
al
bhk
jurkat
bjab
kruger
et
al
deriv
lusso
et
al
cell
incub
roswel
park
memori
institut
medium
rpmi
biowest
nuaill
franc
cell
cultur
eagl
minim
essenti
medium
emem
biochrom
berlin
germani
media
supplement
fb
vv
paa
pasch
austria
lglutamin
mm
lonza
vervier
belgium
human
sera
chikv
denv
obtain
bernhard
nocht
institut
tropic
medicin
hamburg
germani
serum
chikv
obtain
robertkochinstitut
berlin
germani
human
serum
nr
obtain
healthi
volunt
human
sera
use
taken
consent
patient
diagnost
purpos
accord
ethic
regul
germani
gene
chikv
envelop
polyprotein
synthes
geneart
life
technolog
darmstadt
germani
basi
prototyp
sequenc
codonoptim
express
mammalian
cell
gene
clone
via
blunt
end
paci
asci
plasmid
digest
smai
clontechtakara
saintgermainenlay
franc
furthermor
plasmid
pmdlgprre
prsvrev
prrlsincmvgfppr
dull
et
al
pcsiiluc
agarw
et
al
kind
gift
n
somia
r
phitg
encod
vsvg
soneoka
et
al
pgalv
tm
encod
modifi
galv
env
stitz
et
al
use
product
vector
particl
prepar
pei
transfect
solut
g
polyethylenimin
mix
ml
purifi
water
afterward
anoth
ml
purifi
water
ad
follow
shake
total
dissolv
pei
ml
mixtur
ad
ml
purifi
water
ml
solut
mix
anoth
ml
purifi
water
ph
adjust
n
hcl
subsequ
pei
solut
fill
purifi
water
total
weight
g
mix
well
steril
filter
filter
sartoriu
aliquot
store
c
boussif
et
al
hek
cell
seed
cm
dish
ml
dmem
h
subconflu
cell
densiti
cotransfect
plasmid
prrlsincmvgfppr
pcsiiluc
g
pmdlgprre
g
prsvrev
g
phitg
g
respect
use
l
pei
solut
pei
mix
plasmid
dna
volum
ml
serumfre
dmem
incub
min
room
temperatur
subsequ
ad
cell
transfect
lipofectamin
accord
manufactur
protocol
life
technolog
follow
amount
plasmid
dna
use
prrlsincmvgfppr
pcsiiluc
g
pmdlgprre
g
prsvrev
g
phitg
g
respect
h
incub
medium
replac
ml
fresh
dmem
per
dish
anoth
h
later
vector
particl
contain
supernat
harvest
steril
filter
filter
sartoriu
germani
ultracentrifug
h
rpm
rotor
tla
optima
tlx
ultracentrifug
beckman
coulter
krefeld
germani
particl
resuspend
dmem
andor
frozen
c
transduct
cell
vector
particl
produc
gfp
encod
plasmid
cell
respect
cell
line
per
well
seed
ml
volum
plate
one
day
prior
transduct
human
hematopoiet
cell
transduct
carri
directli
count
cell
adher
cell
line
h
seed
medium
remov
replac
dmem
contain
lentivir
vector
particl
eithervsvg
galv
tm
chikv
env
pseudotyp
volum
l
h
incub
c
medium
chang
perform
substitut
supernat
ml
fresh
dmem
cell
incub
anoth
h
c
analyz
flow
cytometri
cell
trypsin
trypsin
edta
lonza
wash
twice
ml
pb
fb
fix
l
pb
paraformaldehyd
subsequ
gfp
signal
detect
lsr
ii
sorp
flow
cytomet
becton
dickinson
compani
heidelberg
germani
transduct
cell
luciferas
encod
lentivir
vector
luciferas
assay
perform
seed
hek
cell
per
well
white
cellstar
microtit
plate
greiner
bioon
frickenhausen
germani
volum
l
dmem
use
multiflo
micropl
dispens
biotek
bad
friedrichshal
germani
h
incub
c
l
vector
particl
either
vsvg
chikv
env
pseudotyp
produc
pcsiiluc
plu
l
dilut
human
serum
ad
cell
use
matrix
multichannel
equal
electron
pipett
thermo
scientif
serum
dilut
rang
time
dilut
mix
vector
particl
result
final
dilut
sera
dilut
dmem
vector
particlesera
mixtur
incub
plate
thermo
scientif
rockford
il
usa
c
h
subsequ
ad
plate
everi
dilutionwel
plate
l
transfer
three
well
plate
triplic
assay
h
incub
l
britelit
perkinelm
rodgau
germani
substrat
ad
well
use
multiflo
micropl
dispens
biotek
bad
friedrichshal
germani
follow
incub
min
room
temperatur
luciferas
signal
detect
pherastar
fs
bmg
labtech
ortenberg
germani
western
blot
perform
biorad
semidri
blotter
protein
separ
sdspage
blot
onto
pvdf
membran
mm
sodium
borat
ph
methanol
sd
per
membran
min
afterward
membran
block
rotiblock
tm
protein
detect
custom
made
polyclon
antibodi
eurogentec
cologn
germani
antirabbit
hrp
coupl
secondari
antibodi
ecl
detect
system
amersham
freiburg
lentivir
vector
particl
pseudotyp
chikv
glycoprotein
gener
transfect
cell
follow
plasmid
lentivir
vector
genom
encod
green
fluoresc
protein
gfp
lentivir
packag
vector
plasmid
encod
codonoptim
chikv
glycoprotein
two
day
transfect
cell
supernat
concentr
ultracentrifug
pellet
well
cell
lysat
subject
western
blot
analysi
cell
lysat
clear
signal
could
observ
antibodi
direct
fig
western
blot
analysi
pellet
cell
supernat
reveal
high
level
chikv
incorpor
lentivir
vector
particl
fig
detect
presenc
capsid
protein
fig
lower
panel
next
proven
pseudotyp
lentivir
vector
infecti
display
cellular
tropism
chikv
seri
tissu
cultur
cell
line
transduc
either
chikvor
vsvgpseudotyp
vector
encod
gfp
transduct
effici
determin
flow
cytometri
lentivir
vector
pseudotyp
vesicular
stomat
viru
g
protein
vsvg
use
posit
control
sinc
well
known
broad
cellular
tropism
chikvpseudotyp
vector
use
transduc
wide
varieti
mous
rabbit
hamster
monkey
human
cell
line
extens
agreement
publish
data
salvador
et
al
fig
contrast
hematopoiet
cell
line
unaffect
chikvpseudotyp
vector
although
vsvg
pseudotyp
vector
abl
transduc
fig
salvador
et
al
gener
titer
chikvpseudotyp
vector
lower
vsvgpseudotyp
vector
block
phdepend
entri
pathway
addit
chloroquin
transduct
process
occur
expect
vsvg
chikvpseudotyp
vector
gibon
ape
leukemia
viru
galv
pseudotyp
vector
affect
chloroquin
entri
phdepend
fig
screen
larg
number
serum
sampl
diagnost
compound
librari
drug
develop
requir
optim
assay
system
largescal
format
advantag
partial
autom
approach
includ
substanti
increas
throughput
data
qualiti
reproduc
automat
process
requir
easili
quantifi
readout
therefor
chikvpseudotyp
vector
system
adjust
vector
construct
initi
gfpencod
vector
replac
vector
encod
firefli
luciferas
pcsiiluc
improv
data
analysi
sinc
whole
well
readout
luminesc
perform
superior
fluoresc
readout
mediumthroughput
highthroughput
approach
furthermor
luminesc
signal
stabl
depend
substrat
halflif
h
assay
use
flexibl
variou
multiwel
format
sensit
low
signaltonois
ratio
outperform
standard
fluorometr
colorimetr
assay
addit
chikvpseudotyp
vector
product
optim
chang
transfect
reagent
use
lipofectamin
increas
number
infecti
particl
releas
produc
cell
compar
transfect
reagent
polyethylenimin
pei
assay
also
optim
plate
format
chang
reaction
volum
l
target
cell
cell
first
seed
well
use
autom
liquid
dispens
subsequ
chikvpseudotyp
vector
particl
serial
dilut
patient
sera
ad
well
transduct
target
cell
chikvpseudotyp
vector
particl
could
inhibit
serum
chikvinfect
patient
dose
depend
manner
measur
luciferas
activ
lowest
dilut
reduc
luciferas
activ
wherea
highest
dilut
almost
effect
luciferas
activ
fig
phenomenon
could
observ
vsvg
pseudotyp
vector
particl
fig
addit
human
serum
slightli
chang
transduct
rate
measur
luciferas
activ
effect
luciferas
activ
incub
chikvpseudotyp
vector
particl
sera
dengu
viru
infect
fig
highthroughput
analysi
patient
serum
serum
chikv
infect
patient
dengu
viru
infect
patient
healthi
control
serial
dilut
incub
chikv
env
pseudotyp
vector
particl
analyz
neutral
activ
detect
rel
luciferas
activ
luciferas
activ
shown
percentag
rel
untreat
control
b
serum
chikv
infect
patient
dengu
viru
infect
patient
healthi
control
serial
dilut
incub
vsvg
pseudotyp
vector
particl
analyz
neutral
activ
detect
rel
luciferas
activ
luciferas
activ
shown
percentag
rel
untreat
control
valu
repres
mean
valu
triplic
measur
patient
normal
healthi
control
fig
vsvg
pseudotyp
vector
particl
consider
affect
treatment
sera
chikvinfect
patient
sera
furthermor
analyz
reactiv
toward
chikv
strain
immunofluoresc
serum
number
one
show
lowest
reactiv
wherea
sera
two
three
titer
either
respect
fig
differ
amount
chikvspecif
igg
also
reflect
neutral
assay
serum
number
inhibit
transduct
target
cell
less
effici
sera
two
three
differ
among
two
highli
reactiv
sera
detect
indic
amount
antibodi
directli
correl
neutral
activ
serum
number
two
contain
addit
chikvspecif
igm
indic
sampl
obtain
earli
infect
might
explain
high
neutral
activ
mani
vaccin
reli
gener
neutral
antibodi
effect
block
initi
viral
infect
result
would
also
desir
chikv
vaccin
sinc
acut
chikv
infect
phase
persist
polyarthr
frequent
occur
patient
laboratori
diagnosi
viral
infect
usual
confin
detect
virusspecif
antibodi
blood
detect
viru
antigen
detect
viral
genet
materi
howev
assay
limit
provid
function
data
unabl
instanc
nucleic
acid
amplif
use
virem
phase
chikv
infect
determin
neutral
activ
antibodi
drug
convent
neutral
assay
like
plaqu
reduct
assay
inhibit
cytopathogen
effect
time
consum
reli
use
fulli
infecti
human
pathogen
reliabl
refer
stock
viru
effort
improv
method
describ
recent
neutral
assay
base
chikv
replicon
express
secret
gaussia
luciferas
gluc
readout
recent
describ
author
show
convinc
data
neutral
antisera
chikv
infect
patient
format
glasker
et
al
howev
product
replicon
requir
vitro
transcript
electropor
step
may
resembl
technic
hurdl
addit
replicon
still
bear
residu
danger
recombin
gener
fulli
replic
chikv
although
readout
luciferas
supernat
cell
benefit
omit
cell
lysi
second
novel
approach
use
pseudotyp
lentivir
vector
particl
kishishita
et
al
vector
particl
need
purifi
sucros
cushion
centrifug
assay
format
base
assay
perform
manual
total
took
day
therefor
method
describ
detect
neutral
activ
use
pseudotyp
lentivir
vector
particl
highthroughput
format
improv
semiautom
neutral
assay
chikv
establish
use
pseudotyp
vector
particl
quantit
luciferas
activ
assay
sever
advantag
neutral
assay
perform
lower
biosafeti
level
thu
requir
handl
human
pathogen
final
autom
perform
assay
includ
seed
target
cell
make
fast
day
conveni
develop
entri
inhibitor
chikv
high
throughput
screen
use
pin
tool
specif
liquid
handl
high
throughput
screen
equip
addit
assay
also
help
chikv
vaccin
develop
screen
larg
number
serum
sampl
clinic
trial
easi
perform
function
assay
fast
detect
neutral
crossreact
neutral
antibodi
speed
chikv
possibl
alphaviru
vaccin
develop
might
use
basic
research
studi
alphavirusspecif
neutral
immun
respons
larg
outbreak
safe
fast
semiautom
high
throughput
assay
detect
chikv
entri
inhibitor
develop
